Modern approaches to HLA-haploidentical blood or marrow transplantation
CG Kanakry, EJ Fuchs, L Luznik - Nature reviews Clinical oncology, 2016 - nature.com
Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …
treatment for a variety of haematological malignancies and nonmalignant diseases …
The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China
Y Wang, H Chen, J Chen, M Han, JD Hu, J Hu… - Cancer Letters, 2018 - Elsevier
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important curative
therapy for patients with leukemia. However, relapse remains the leading cause of death …
therapy for patients with leukemia. However, relapse remains the leading cause of death …
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation
H Guo, YJ Chang, Y Hong, LP Xu, Y Wang… - Cellular & molecular …, 2021 - nature.com
Haploidentical stem cell transplantation (haplo-SCT) achieves superior or at least
comparable clinical outcomes to HLA-matched sibling donor transplantation (MSDT) in …
comparable clinical outcomes to HLA-matched sibling donor transplantation (MSDT) in …
[HTML][HTML] Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as …
YJ Chang, Y Wang, YR Liu, LP Xu, XH Zhang… - Journal of hematology & …, 2017 - Springer
Background This study compared the effects of pre-transplantation minimal residual disease
(pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched …
(pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched …
Long‐term follow‐up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at …
Y Wang, DH Liu, KY Liu, LP Xu, XH Zhang, W Han… - Cancer, 2013 - Wiley Online Library
BACKGROUND: Many patients who require allogeneic hematopoietic stem cell
transplantation (allo‐HSCT) lack a human leukocyte antigen (HLA)‐matched donor …
transplantation (allo‐HSCT) lack a human leukocyte antigen (HLA)‐matched donor …
Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first …
S Yu, F Huang, Y Wang, Y Xu, T Yang, Z Fan, R Lin… - Leukemia, 2020 - nature.com
This study aimed to investigate graft-versus-leukemia (GVL) of haploidentical donor (HID)
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …
T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT
Y Luo, H Xiao, X Lai, J Shi, Y Tan, J He… - Blood, The Journal …, 2014 - ashpublications.org
We developed an approach of T-cell-replete haploidentical hematopoietic stem cell
transplantation (HSCT) with low-dose anti-T-lymphocyte globulin and prospectively …
transplantation (HSCT) with low-dose anti-T-lymphocyte globulin and prospectively …
Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist
N Kekre, JH Antin - Blood, The Journal of the American Society …, 2014 - ashpublications.org
Most patients who require allogeneic stem cell transplantation do not have a matched
sibling donor, and many patients do not have a matched unrelated donor. In an effort to …
sibling donor, and many patients do not have a matched unrelated donor. In an effort to …
Donor‐derived CD 19‐targeted T cell infusion induces minimal residual disease‐negative remission in relapsed B‐cell acute lymphoblastic leukaemia with no …
Y Chen, Y Cheng, P Suo, C Yan… - British journal of …, 2017 - Wiley Online Library
Relapse is a common cause of failure in patients with B‐cell acute lymphoblastic leukaemia
(B‐ALL) after haploidentical haematopoietic stem cell transplantation (haplo‐HSCT), and …
(B‐ALL) after haploidentical haematopoietic stem cell transplantation (haplo‐HSCT), and …
Haploidentical hematopoietic transplantation: current status and future perspectives
Y Reisner, D Hagin, MF Martelli - Blood, The Journal of the …, 2011 - ashpublications.org
For patients with hematologic malignancies at high risk of relapse who do not have matched
donors, a suitable alternative stem cell source is the HLAhaploidentical 2 or 3-loci …
donors, a suitable alternative stem cell source is the HLAhaploidentical 2 or 3-loci …